ADR News Bulletin 2020 September (Volume 22 Number 2)

Bulletin Highlights:

  • Conditional approval of remdesivir (Veklury®) for COVID-19 infection in Singapore 
  • Temporary suspension of sales of Esmya™ (ulipristal acetate) Tablet 5mg 
  • Risk of venous thromboembolism with tofacitinib
  • Risk of orofacial malformations associated with the use of ondansetron in early pregnancy
  • AE Case in Focus: Test Yourself -  What could have caused the acute kidney injury in this patient?

Click on the link below to download the issue in PDF:

ADR_News_Sep2020_Vol22_No21566 KB

Healthcare professional, Industry member, Therapeutic Products
Published:

Adverse Drug Reaction News Bulletins

23 Sep 2020
Doctors, dentists and pharmacists can claim continuing education points for reading each issue of the HSA ADR News Bulletin. Doctors can apply for one non-core Continuing Medical Education (CME) point under category 3A, dentists can apply for one Continuing Professional Education (CPE) point under category 3A and pharmacists can apply for one patient-care Continuing Professional Education (CPE) point under category 3A per issue of the bulletin. Each issue of the bulletin is valid for two years.